esophagitis/구역질

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs

BACKGROUND OF THE INVENTION This invention relates to benzisoxazole derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the treatment

BACKGROUND OF THE INVENTION This invention relates to Indazole Derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the treatment of

BACKGROUND OF THE INVENTION This invention relates to Oxyindole Derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the treatment of

TECHNICAL FIELD This invention relates to novel benzimidazolone compounds. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, a method of treatment and use comprising the above compounds for the treatment of

This invention relates to a class of spirocyclic compounds which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with

BACKGROUND OF THE INVENTION This invention relates to benzimidazolone carboxylic acid derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives

BACKGROUND OF THE INVENTION This invention relates to benzimidazolone carboxylic acid derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives

BACKGROUND OF THE INVENTION This invention relates to benzimidazolone carboxylic acid derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives

FIELD The present disclosure relates to bulk compositions and pharmaceutical compositions comprising a trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1- -yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt, and methods of

This invention relates to heterocyclic compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which act upon 5-hydroxytryptamine (5HT) receptors of the type located on terminals of

This invention relates to heterocyclic compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which act upon 5-hydroxytryptamine (5-HT) receptors of the type located on terminals of

This invention relates to a new medical use for a group of heterocyclic compounds and pharmaceutical compositions containing them. In particular it relates to certain tetrahydrocarbazolone derivatives which may be used to promote gastric emptying and as anti-emetic agents. A particularly important